Vanda Pharmaceuticals Inc. has entered into an Asset Purchase Agreement with Actelion Pharmaceuticals Ltd. to acquire the U.S. and Canadian rights for PONVORY, a treatment for multiple sclerosis, for an upfront payment of $100 million.